Abstract 2070P
Background
Healthy lifestyle habits such as avoiding overweight, engaging in moderate physical activity for at least 150 minutes per week, and getting good quality sleep have not only been shown to decrease the incidence of certain cancers, but also have a clear impact on the outcome of patients diagnosed with breast cancer. Adherence to these recommendations has an impact on quality of life, and some studies suggest their beneficial effect on patient survival.
Methods
We included 181 patients diagnosed with breast cancer in different stages, Multivariable ambulatory circadian monitoring of skin temperature, motor activity, light exposure, and sleep patterns was performed for 7 consecutive days through a small watch-like device called Kronowise 3.0. The patients are divided into 3 groups: group 1 includes metastatic patients, group 2 consists of patients with early-stage breast cancer undergoing chemotherapy, and group 3 comprises patients with early-stage breast cancer under follow-up (more than 1 year after the completion of chemotherapy).
Results
The table describes the mean age with standard deviation, physical activity categorized as patients who achieve ≥ 150 minutes of moderate physical activity (MPA) per week, ≥ 300 minutes of moderate physical activity per week, ≥ 75 minutes of vigorous physical activity per week, patients with good sleep hygiene (between 7 and 9 hours of sleep per day), patients with < 10 hours of sedentary behavior, and the percentage of patients with overweight and obesity in each group. Table: 2070P
Median Age | MPA ≥ 150 min | MPA ≥ 300 min | Vigorous activity ≥ 75 min | Sedentariness < 10 hours | Median night sleep (hours) | Median BMI | BMI 25-30 | BMI ≥ 30 | |
GROUP 1 | 57 ± 9 | 65% | 45% | 4% | 90% | 7.5 | 25.53 | 21% | 20% |
GROUP 2 | 50 ± 7 | 88% | 73% | 15% | 100% | 6.7 | 23.26 | 15% | 5% |
GROUP 3 | 55 ± 10 | 89% | 79% | 20% | 100% | 6.5 | 26 | 20% | 17% |
Conclusions
Despite breast cancer patients not being sedentary and having higher levels of moderate physical activity compared to the general population, the occurrence of vigorous physical activity is quite low among these patients. It is imperative to establish proper sleep hygiene in these patients in order to improve parameters and reduce the rates of overweight and obesity, particularly among the metastatic population and long-term survivors, where these rates are significantly higher.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This abstract is part of the CLARIFY project that has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under grant agreement No. 875160.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2076P - Topical diclofenac for prevention of HFS in patients receiving capecitabine monotherapy: An exploratory subgroup analysis of the D-ToRCH phase III trial
Presenter: Akhil Santhosh
Session: Poster session 06
2077P - A randomized, placebo-controlled trial assessing the efficacy and safety of the combination of superoxide dismutase, alpha lipoic acid, vitamin B12, B1, B2, B6, E, Mg, Zn and a fatty acid for 6 months in the management of chemotherapy induced neuropathic pain
Presenter: Triantafylos Didangelos
Session: Poster session 06
2078P - Evaluation of chemotherapy-induced nausea and vomiting beyond the delayed phase: Results of a survey of healthcare providers in Japan
Presenter: Florian Scotté
Session: Poster session 06
2079P - Naloxegol for the treatment of opioid-induced constipation in patients with cancer pain: A pooled analysis of real-world studies (NALOPOOL)
Presenter: Maria del Carmen Beato Zambrano
Session: Poster session 06
2080P - Incidence and risks of intravenous chemotherapy-induced neutropenia (ICIN) in oncology: A multicenter retrospective cohort study on real-life data
Presenter: Olivia Rohr
Session: Poster session 06
2081P - The therapeutic effect of anti-inflammatory tripeptide cream on hand-foot syndrome related to anticancer drugs: A prospective, randomized, placebo-controlled pilot trial
Presenter: Yaewon Yang
Session: Poster session 06
2082P - TASMAN: An international survey on the knowledge, aTtitudes and clinical pAtternsS of use of Medical Cannabis for caNcer care
Presenter: Marco Filetti
Session: Poster session 06
2083P - Association between VTE location and risk of recurrent, bleeding and death in the international prospective TESEO SEOM cancer cohort
Presenter: Rocío Martín Lozano
Session: Poster session 06
2084P - Cardiovascular (CV) mortality among metastatic cancer patients: A retrospective cohort study
Presenter: Irbaz Riaz
Session: Poster session 06
2085P - Buprenorphine use and cancer outcomes
Presenter: Nosayaba Osazuwa-Peters
Session: Poster session 06